Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant radiotherapy followed by atezolizumab and bevacizumab for low- to intermediate-risk rectal cancer
NL-OMON58952Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in rectal cancer and rectal adenocarcinoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical complete and near-complete response rate. Started Sep 2019; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON58952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58952.